MX2022010378A - Formulacion de daptomicina. - Google Patents

Formulacion de daptomicina.

Info

Publication number
MX2022010378A
MX2022010378A MX2022010378A MX2022010378A MX2022010378A MX 2022010378 A MX2022010378 A MX 2022010378A MX 2022010378 A MX2022010378 A MX 2022010378A MX 2022010378 A MX2022010378 A MX 2022010378A MX 2022010378 A MX2022010378 A MX 2022010378A
Authority
MX
Mexico
Prior art keywords
formulation
solid
daptomycin
present description
daptomicin
Prior art date
Application number
MX2022010378A
Other languages
English (en)
Spanish (es)
Inventor
Barbara Fumic
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of MX2022010378A publication Critical patent/MX2022010378A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022010378A 2020-02-28 2021-02-26 Formulacion de daptomicina. MX2022010378A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982945P 2020-02-28 2020-02-28
PCT/EP2021/054841 WO2021170807A1 (en) 2020-02-28 2021-02-26 Daptomycin formulation

Publications (1)

Publication Number Publication Date
MX2022010378A true MX2022010378A (es) 2022-09-21

Family

ID=74797935

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010378A MX2022010378A (es) 2020-02-28 2021-02-26 Formulacion de daptomicina.

Country Status (9)

Country Link
US (1) US12629337B2 (cg-RX-API-DMAC7.html)
EP (1) EP4110303A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023516957A (cg-RX-API-DMAC7.html)
CN (2) CN118873500A (cg-RX-API-DMAC7.html)
AU (1) AU2021227095B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022015571A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022010378A (cg-RX-API-DMAC7.html)
WO (1) WO2021170807A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208343B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759497B2 (en) 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
WO2026111848A1 (en) * 2024-11-21 2026-05-28 MAIA Pharmaceuticals, Inc. Daptomycin compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU2001267011B2 (en) 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
JP2003055256A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第xiii因子製剤
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US20110124551A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
WO2013103801A1 (en) 2012-01-04 2013-07-11 Hospira, Inc. Pharmaceutical spray drying
NO2887953T3 (cg-RX-API-DMAC7.html) 2012-08-23 2018-03-10
PL4066849T3 (pl) 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
WO2016098009A1 (en) 2014-12-16 2016-06-23 Dr. Reddy’S Laboratories Limited Lyophilized injectable compositions of daptomycin
CN106943587B (zh) 2016-01-06 2021-06-22 山东新时代药业有限公司 一种注射用达托霉素冻干粉针及其制备工艺
US11759497B2 (en) * 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
GB201718888D0 (en) * 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation

Also Published As

Publication number Publication date
JP2025142200A (ja) 2025-09-30
US20230068866A1 (en) 2023-03-02
BR112022015571A2 (pt) 2022-09-27
AU2021227095A1 (en) 2022-08-25
EP4110303A1 (en) 2023-01-04
CN118873500A (zh) 2024-11-01
WO2021170807A1 (en) 2021-09-02
CN115038431B (zh) 2024-08-09
US12629337B2 (en) 2026-05-19
JP2023516957A (ja) 2023-04-21
AU2021227095B2 (en) 2024-02-22
CA3168727A1 (en) 2021-09-02
CN115038431A (zh) 2022-09-09
ZA202208343B (en) 2024-11-27

Similar Documents

Publication Publication Date Title
ZA202208343B (en) Daptomycin formulation
BR112021023457A2 (pt) Composto, uso do composto, composição, e, métodos para preparar a composição e um composto
CO2023014807A2 (es) Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras
CO5690620A2 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor egf
PE20121405A1 (es) Excipiente solubilizante para vacunas de virus completo inactivado
MX2020001885A (es) Formulaciones de daptomicina.
MX2022007275A (es) Composiciones de acidos biliares y compuestos de fenilbutirato.
CO6630170A2 (es) Composición de silicato disuelta estabilizada por al menos dos osmolitos seleccionados.
MX2023002117A (es) Forma amorfa de un inhibidor de malt1 y formulaciones de este.
BR112013017884A2 (pt) varredura de microcolônia encapsulada com gel
MX2021004146A (es) Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
MY156772A (en) Composition and method for controlling plant diseases description
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
PH12017501503B1 (en) Acid composition based on leonardite and amino acids
AR123165A1 (es) Un método para la producción de composiciones protéicas
CO2021013926A2 (es) Glicoproteínas sialiladas
WO2021061064A3 (en) Ultrasonic aeroponic indoor plant cultivation modules
CL2024003023A1 (es) Inhibidores lrrk2.
PE20181403A1 (es) Hidrolisis enzimatica parcial de triacilgliceroles
CL2024002285A1 (es) Procesos para la preparación de alfa-hidroxi ésteres por esterificación de alfa-hidroxiácidos
DOP2022000222A (es) Formulación estable
MX2019010555A (es) Anticuerpo anti-pd-l1 para detectar pd-l1.
MX2024007018A (es) Sintesis de glufosinato mediante el uso de un proceso basado en hidantoinasa.
PH12020551154A1 (en) Method for suppressing discoloration of external composition containing adenosine phosphate and tranexamic acid
BR112018070033A2 (pt) preparação enzimática, método para produzir um produto de pancreatina, composição farmacêutica e método para tratar insuficiência pancreática exócrina